An Evolutionary and Neuroendocrine Hypothesis for the Reversal and Prevention of Schizophrenia: Integrating Oxytocinergic Modulation, Circadian Control, and Anti-Inflammatory Interventions

Schizophrenia is traditionally viewed through a dopaminergic lens, but it is increasingly recognized as a heterogeneous neurodevelopmental condition. While the NMDA receptor hypofunction model suggests an upstream mechanism for psychosis, this paper proposes an evolutionary and neuroendocrine counterfactual: the functional impact of reduced NMDA activity depends heavily on surrounding environmental, metabolic, and social contexts.The author outlines a comprehensive hypothesis involving regulatory failures across the amygdala, hypothalamic-pituitary-adrenal (HPA) axis, prefrontal cortex (PFC), oxytocinergic system, glutamatergic pathways, and mesolimbic circuitry. These alterations drive abnormal salience processing, oxidative stress, and inflammation. Furthermore, ancestral human ecology—including diet, antioxidants, and social buffering—is discussed regarding its historical influence on neuroendocrine and immune regulation, though this remains speculative.The model also addresses a developmental "synaptic pruning spectrum." While excessive or aberrant pruning backed by microglial and complement mechanisms is implicated in schizophrenia, other conditions like autism and ADHD show distinct plasticity profiles. Additionally, chronic glucocorticoid exposure and stress-induced dendritic retraction in the PFC suggest that excessive synaptic loss emerges from an interplay of developmental susceptibility, NMDA dysfunction, inflammation, and chronic stress rather than isolated pruning defects.Finally, the paper introduces an experimental reversal framework utilizing beta-adrenergic modulation, endocannabinoid-system modulation, targeted oxytocinergic stimulation, circadian stabilization, nutritional support, and real-time sensorimotor-gating monitoring. While these interventions target stress, social salience, and neuroplasticity, their clinical efficacy in reversing schizophrenia remains to be demonstrated.